Can immunohistochemistry improve the pathological diagnosis of placenta accreta spectrum (PAS) disorders?
Extravillous trophoblast
Immunohistochemistry
Placenta accreta spectrum
Placenta creta
Placenta increta
Placenta percreta
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
03 Aug 2023
03 Aug 2023
Historique:
received:
09
02
2023
accepted:
03
07
2023
medline:
3
8
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
aheadofprint
Résumé
The term of placenta accreta spectrum (PAS) disorder includes all grades of abnormal placentation. It is crucial for pathologist provide standardized diagnostic assessment to evaluate the outcome of management strategies. Moreover, a correct and safe diagnosis is useful in the medico-legal field when it becomes difficult for the gynecologist to demonstrate the suitability and legitimacy of demolitive treatment. The purposes of our study were: (1) to assess histopathologic features according to the recent guidelines; (2) to determine if immunohistochemistry can be useful to identify extravillous trophoblast (EVT) and to measure the depth of infiltration into the myometrium to improve the diagnosis of PAS. The retrospective study was conducted on 30 cases of gravid hysterectomy with histopathologic diagnosis of PAS. To identify the depth of EVT, immunohistochemical stainings were performed using anti MNF116 (cytokeratins 5, 6, 8, 17, 19), actin-SM, HPL (Human Placental Lactogen), vimentin and GATA3 antibodies. Our cases were graded based on the degree of invasion of the myometrium. Ten were grade 1 (33.3%), 12 grade 2 (40%) and 8 grade 3A (26.7%). EVT invasion was best seen and evident by double immunostainings with actin-SM and cytokeratins, actin-SM and HPL, actin-SM and GATA3. The role of pathologist is decisive to determine the different grades of PAS. A better understanding of the depth of myometrial invasion can be achieved by the use of immunohistochemistry affording an important tool to obtain reproducible grading of PAS. This purpose is crucial in the setting of postoperative quality reviews and particularly in the forensic medicine field.
Identifiants
pubmed: 37535133
doi: 10.1007/s00404-023-07143-0
pii: 10.1007/s00404-023-07143-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Irving FC, Hertig AT (1937) A study of placenta accreta. Surg Gynecol Obstet 64:178–200
Luke RK, Sharpe JW, Greene RR (1966) Placenta accreta: the adherent or invasive placenta. Am J Obstet Gynecol 95:660–668. https://doi.org/10.1016/s0002-9378(16)34741-x
doi: 10.1016/s0002-9378(16)34741-x
pubmed: 5942637
Collins SL, Stevenson GN, Al-Khan A, Illsley NP, Impey L, Pappas L, Zamudio S (2015) Three-Dimensional Power Doppler Ultrasonography for Diagnosing Abnormally Invasive Placenta and Quantifying the Risk. Obstet Gynecol 126:645–653. https://doi.org/10.1097/AOG.0000000000000962
doi: 10.1097/AOG.0000000000000962
pubmed: 26214694
pmcid: 6428069
Jauniaux E, Collins S, Burton GJ (2018) Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am J Obstet Gynecol 218:75–87. https://doi.org/10.1016/j.ajog.2017.05.067
doi: 10.1016/j.ajog.2017.05.067
pubmed: 28599899
Jauniaux E, Chantraine F, Silver RM, Langhoff-Roos J; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel (2018) FIGO consensus guidelines on placenta accreta spectrum disorders: epidemiology. Int J Gynaecol Obstet 140:265–273. https://doi.org/10.1002/ijgo.12407
doi: 10.1002/ijgo.12407
Jauniaux E, Ayres-de-Campos D; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel (2018) FIGO consensus guidelines on placenta accreta spectrum disorders: introduction. Int J Gynaecol Obstet 140:261–264. https://doi.org/10.1002/ijgo.12406
doi: 10.1002/ijgo.12406
Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, Fox KA, Collins S; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel (2019) FIGO classification for the diagnosis of placental accreta spectrum disorders. Int J Gynaecol Obstet 146:20–24. https://doi.org/10.1002/ijgo.12761
doi: 10.1002/ijgo.12761
Hecht JL, Baergen R, Ernst LM, Katzman PJ, Jacques SM, Jauniaux E, Khong TY, Metlay LA, Poder L, Qureshi F, Rabban JT 3rd, Roberts DJ, Shainker S, Heller DS (2020) Classification and reporting guidelines for the pathology diagnosis of placenta accrete spectrum (PAS) disorders: recommendations from an expert panel. Mod Pathol 33:2382–2396. https://doi.org/10.1038/s41379-020-0569-1
doi: 10.1038/s41379-020-0569-1
pubmed: 32415266
Baergen RN (2011) Manual of pathology of the human placenta. Springer, Boston, pp 192–202
doi: 10.1007/978-1-4419-7494-5
Parra-Herran C, Djordjevic B (2016) Histopathology of placenta creta: chorionic villi intrusion into myometrial vascular spaces and extravillous trophoblast proliferation are frequent and specific findings with implications for diagnosis and pathogenesis. Int J Gynecol Pathol 35:497–508. https://doi.org/10.1097/PGP.0000000000000250
doi: 10.1097/PGP.0000000000000250
pubmed: 26630223
Bartels HC, Postle JD, Downey P, Brennan DJ (2018) Placenta accreta spectrum: a review of pathology, molecular biology, and biomarkers. Dis Markers 2018:1507674. https://doi.org/10.1155/2018/1507674
doi: 10.1155/2018/1507674
pubmed: 30057649
pmcid: 6051104
Thurn L, Lindqvist PG, Jakobsson M, Colmorn LB, Klungsoyr K, Bjarnadóttir RI, Tapper AM, Børdahl PE, Gottvall K, Petersen KB, Krebs L, Gissler M, Langhoff-Roos J, Källen K (2016) Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries. BJOG 123:1348–1355. https://doi.org/10.1111/1471-0528.13547
doi: 10.1111/1471-0528.13547
pubmed: 26227006
Morlando M, Collins S (2020) Placenta accreta spectrum disorders: challenges, risks, and management strategies. Int J Wom Health 12:1033–1045. https://doi.org/10.2147/IJWH.S224191
doi: 10.2147/IJWH.S224191
Bhide A, Sebire N, Abuhamad A, Acharya G, Silver R (2017) Morbidly adherent placenta: the need for standardization. Ultrasound Obstet Gynecol 49:559–563. https://doi.org/10.1002/uog.17417
doi: 10.1002/uog.17417
pubmed: 28120421
Morel O, Collins SL, Uzan-Augui J, Masselli G, Duan J, Chabot-Lecoanet AC, Braun T, Langhoff-Roos J, Soyer P, Chantraine F; International Society for Abnormally Invasive Placenta (IS-AIP) (2019) A proposal for standardized magnetic resonance imaging (MRI) descriptors of abnormally invasive placenta (AIP) - From the International Society for AIP. Diagn Interv Imaging 100:319–325. https://doi.org/10.1016/j.diii.2019.02.004
doi: 10.1016/j.diii.2019.02.004
Jauniaux E, Bhide A, Kennedy A, Paula Woodward, Corrine Hubinont, Sally Collins; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel (2018) FIGO consensus guidelines on placenta accreta spectrum disorders: prenatal diagnosis and screening. In J Gynaecol Obstet 140:274–280. https://doi.org/10.1002/ijgo.12408
doi: 10.1002/ijgo.12408
Eller AG, Bennett MA, Sharshiner M, Masheter C, Soisson AP, Dodson M, Silver RM (2011) Maternal morbidity in cases of placenta accreta managed by a multidisciplinary care team compared with standard obstetric care. Obstet Gynecol 117:331–337. https://doi.org/10.1097/AOG.0b013e3182051db2
doi: 10.1097/AOG.0b013e3182051db2
pubmed: 21309195
Kurman RJ (1991) The morphology, biology, and pathology of intermediate trophoblast: a look back to the present. Hum Pathol 22:847–855
doi: 10.1016/0046-8177(91)90173-M
pubmed: 1655617
Philippe E, Charpin C (1992) Pathologie Gynécologique etObstétricale. Masson, New Delhi, p 333
Tantbirojn P, Crum CP, Parast MM (2008) Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast. Placenta 29:639–645. https://doi.org/10.1016/j.placenta.2008.04.008
doi: 10.1016/j.placenta.2008.04.008
pubmed: 18514815
MirkovicJ EK, Drapkin R, Barletta JA, Quade B, Hirsch MS (2015) GATA3 expression in gestational trophoblastic tissues and tumours. Histopathology 67:634–644. https://doi.org/10.1111/his.12681
doi: 10.1111/his.12681
Heller DS, Wyand R, Cramer S (2019) Recurrence of basal plate myofibers, with further consideration of pathogenesis. Fetal Pediatr Pathol 38:30–43
doi: 10.1080/15513815.2018.1546356
pubmed: 30588864
Kohnen G, Kertschanska S, Demir R, Kaufmann P (1996) Placental villous stroma as a model system for myofibroblast differentiation. Histochem Cell Biol 105:415–429. https://doi.org/10.1007/BF01457655
doi: 10.1007/BF01457655
pubmed: 8791101
Losi L, Bertolini F, Guaitoli G, Fabbiani L, Banchelli F, Ambrosini-Spaltro A, Botticelli L, Scurani L, Baldessari C, Barbieri F, Cascinu S, Maiorana A (2019) Role of evaluating tumor-infiltrating lymphocytes, programmed death-1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma. Int J Oncol 55:1157–1164. https://doi.org/10.3892/ijo.2019.4883
doi: 10.3892/ijo.2019.4883
pubmed: 31545419
Kim KR, Jun SY, Kim JY, Ro JY (2004) Implantation site intermediate trophoblasts in placenta cretas. Mod Pathol 17:1483–1490. https://doi.org/10.1038/modpathol.3800210
doi: 10.1038/modpathol.3800210
pubmed: 15205687
Benirschke K, Kaufmann P, Baergen RN (2006) Pathology of the Human Placenta, 5th edn. Springer-Verlag, New York
Jauniaux E, Kingdom JC, Silver RM (2021) A comparison of recent guidelines in the diagnosis and management of placenta accreta spectrum disorders. Best Pract Res Clin Obstet Gynaecol 72:102–116. https://doi.org/10.1016/j.bpobgyn.2020.06.007
doi: 10.1016/j.bpobgyn.2020.06.007
pubmed: 32698993